Citron's Left Said to Take New Short Stake in Valeant Pharma (VRX); Says Worth $0
(Updated - July 13, 2016 12:52 PM EDT)
Citron's Andrew Left said to take a new short stake in Valeant Pharma (NYSE: VRX).
UPDATE - According to RealMoney, Left is calling Valeant a zero.
Commenting on earlier reports that Sequoia Fund exited their entire position, he said: They've sat down and they've seen and they've interviewed and they walked... The fact there they're selling tells everything,
Left said. It's already a sinking ship ... With the Titanic going down you can at least get on a life boat and get out with what you can.
Shares of Valeant are up just 0.3 percent Wednesday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump: will probably let CNN, MSNOW and Politico back in to White House if judge decides
- Microsoft Began A New Round Of Layoffs Affecting Around 500 Employees - Business Insider
- China Probes DeepSeek, Moonshot Over Potential Data Leaks to Anthropic - Information
Create E-mail Alert Related Categories
Short Sales, Trader TalkRelated Entities
Citron ResearchSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share